...
CHRSMICRO

Coherus Oncology, Inc.

HealthcareBiotechnology
$1.67
$0.00(-1.18%)
52W$0.71
$2.62
FinancialsValuationvs RVMD
Updated Mar 3, 12:00 AM
RSI44
RS Rating88/99
Beta1.33
Volatility89%
F-Score5/9
Mkt Cap$194M
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Coherus Oncology, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is leading (RS Rating: 88), indicating clear outperformance against the broad market. Earnings contraction of 232% provides fundamental context to the price action. Investors should exercise caution due to high volatility (89% annualized), which requires wider risk management.

Relative Strength
88
out of 99
Market Leader
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
1.33
vs S&P 500
ABOVE MKT
52W Position
50%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$1.73
50 SMA > 100 SMA$1.60
100 SMA > 150 SMA$1.48
150 SMA > 200 SMA$1.31

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$1.89-11.58%BELOW
50 SMA$1.73-3.66%BELOW
100 SMA$1.60+4.57%ABOVE
150 SMA$1.48+13.02%ABOVE
200 SMA$1.31+27.30%ABOVE

Price Performance

1D-1.2%
1W+3.1%
1M-24.6%
3M+22.8%
6M+41.5%
YTD+21.9%
1Y+50.5%
3Y-37.3%
52-Week Trading Range50% from low
$1.67
52W Low$0.71
52W High$2.62

Technical Indicators

RSI (14)NEUTRAL
44.1
305070
VCP ScoreCOOL
5/10
Base depth: 87.8%

Risk Profile

Beta
1.33
52W Vol
89%
ATR
$0.13
Max DD (1Y)
-40%

Volume Analysis

Today
1
50D Avg
2.62M
Vol Ratio
0.00x
Liquidity
ILLIQUID

Earnings Momentum

Q4'24+38%
$-0.44
Q1'25-160%
$-0.49
Q2'25-227%
$-0.36
Q3'25-232%
$-0.31
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+23.98%
5 Years:-5.60%
3 Years:-6.50%
TTM:-63.60%

Compounded Profit Growth

10 Years:—
5 Years:-27.29%
3 Years:—
TTM:-16.15%

Stock Price CAGR

10 Years:-19.26%
5 Years:-36.38%
3 Years:-37.28%
1 Year:+50.45%

Return on Equity

10Y Avg:-665.4%
5Y Avg:-41.6%
3Y Avg:—
Last Year:176.6%

Key Metrics

Market Cap$194M
Gross Margin56.0%
Net Margin10.7%
Piotroski F-Score5/9

More CHRS Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

CHRS vs RVMDRVMDINCYGMABEXEL

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 88 meansCHRS outperformed 88% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.33 means 33% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 5/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 5/10 with COOL status.

Frequently Asked Questions

Is CHRS in an uptrend right now?

CHRS has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is CHRS overbought or oversold?

CHRS's RSI (14) is 44. The stock is in neutral territory, neither overbought nor oversold.

Is CHRS outperforming the market?

CHRS has a Relative Strength (RS) Rating of 88 out of 99. Yes, CHRS is a market leader, outperforming 88% of all stocks over the past 12 months.

Where is CHRS in its 52-week range?

CHRS is trading at $1.67, which is 64% of its 52-week high ($2.62) and 50% above its 52-week low ($0.71).

How volatile is CHRS?

CHRS has a Beta of 1.33 and 52-week volatility of 89%. It's more volatile than the S&P 500 - expect bigger swings.